Estado de situación y regulación de laboratorios bioanalíticos que cuantifican inmunosupresores para trasplantes en Argentina

Schaiquevich, Paula; Taich, Paula; Riva, Natalia; Leone, Francisco; Paternoster, Nora; Mato, Gabriel; Cáceres Guido, Paulo.
Rev Panam Salud Publica ; 39(3),mar. 2016
Artigo em Espanhol | PAHOIRIS | ID: phr-28307

Documentos relacionados

  1. Estado de situación y regulación de laboratorios bioanalíticos que cuantifican inmunosupresores para trasplantes en Argentina
  2. The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics.
  3. Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities.
  4. Machine Learning Models for Human <i>In Vivo</i> Pharmacokinetic Parameters with In-House Validation.
  5. Determination of the Number of Tissue Groups of Kinetically Distinct Transit Time in Whole-Body Physiologically Based Pharmacokinetic (PBPK) Models I: Theoretical Consideration of Bottom-Up Approach of Lumping Tissues in Whole-Body PBPK.
  6. Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case study.
  7. Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection.
  8. Partnering with Big Pharma-What Academics Need to Know.
  9. Definition of variables required for comprehensive description of drug dosage and clinical pharmacokinetics.
  10. Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview.